

## Sumitomo Pharmaceuticals Co Limited

[View the current Sumitomo Pharmaceuticals Co Limited Page on BioPortfolio.com](http://www.bioportfolio.com/bioporporate/9476-Sumitomo+Pharmaceuticals+Co+Limited.html)

(<http://www.bioportfolio.com/bioporporate/9476-Sumitomo+Pharmaceuticals+Co+Limited.html>)

### Contact Details:

2-8 Doshomachi 2-chome Chuo-ku

Osaka

Osaka

541

Japan

Tel: 81 6 229 5775

Fax: 00 81 6 233 2288

Email:

### Recent Publications by Sumitomo Pharmaceuticals Co Limited:



- [SPF-5506-A4, a new peptaibol inhibitor of amyloid beta-peptide formation produced by Trichoderma sp.](#)  
*A new peptaibol compound, SPF-5506-A4, was isolated from the fermentation...*7th July, 2007  
Exploratory Research Group, Research Division, Sumitomo Pharmaceuticals- J Antibiot (Tokyo). 2007 Mar;60(3):184-90. ([DOI Direct Link](#))
- [Pharmacological profile of SMP-797, a novel acyl-coenzyme a: cholesterol acyltransferase inhibitor with inducible effect on the expression of low-density lipoprotein receptor.](#)  
*We investigated the pharmacological profile of SMP-797, a novel...*28th July, 2006  
Research Division, Sumitomo Pharmaceuticals Co., Ltd., Osaka, Japan.- J Cardiovasc Pharmacol. 2006 Feb;47(2):322-9. ([DOI Direct Link](#))
- [Synthesis and pharmacological profile of an orally-active growth hormone secretagogue, SM-130686.](#)  
*Hypothalamic hormones physiologically regulate pulsatile release of growth...*29th April, 2006  
Sumitomo Pharmaceuticals Co. Ltd., Research Division, Discovery Research- Comb Chem High Throughput Screen. 2006 Mar;9(3):187-96.
- [SPF-32629 A and B, novel human chymase inhibitors produced by Penicillium sp.](#)  
*Two new human chymase inhibitors, SPF-32629A and B, were isolated from the...*21st April, 2006  
Exploratory Research Group, Research Division, Sumitomo Pharmaceuticals- J Antibiot (Tokyo). 2006 Jan;59(1):29-34. ([DOI Direct Link](#))
- [A unique gene expression signature discriminates familial Alzheimer's disease mutation carriers from their wild-type siblings.](#)  
*Alzheimer's disease (AD) is a neurodegenerative disease with an insidious...*21st April, 2006  
Research Division, Sumitomo Pharmaceuticals Co., Ltd., 3-1-98- Proc Natl Acad Sci U S A. 2005 Oct

- 11;102(41):14854-9. Epub 2005 Sep 30. ([DOI Direct Link](#))
- [A novel class of sodium/calcium exchanger inhibitors: design, synthesis, and structure-activity relationships of 4-phenyl-3-\(piperidin-4-yl\)-3,4-dihydro-2\(1H\)-quinazolinone derivatives.](#)  
*Design, synthesis, and structure-activity relationships of...*29th March, 2006  
Research Division, Sumitomo Pharmaceuticals Co. Ltd, 1-98, Kasugadenaka- Bioorg Med Chem Lett. 2006 Feb;16(3):727-30. Epub 2005 Oct 24. ([DOI Direct Link](#))
  - [Identification of phosphodiesterase-1 and 5 dual inhibitors by a ligand-based virtual screening optimized for lead evolution.](#)  
*We identified new lead candidates which showed potent dual inhibition...*24th March, 2006  
Sumitomo Pharmaceuticals Co., Ltd, 1-98, Kasugade Naka 3-Chome,- Bioorg Med Chem Lett. 2006 Mar 1;16(5):1371-9. Epub 2005 Dec 6. ([DOI Direct Link](#))
  - [Synthesis and biological activity of novel 4-phenyl-1,8-naphthyridin-2\(1H\)-on-3-yl ureas: potent acyl-CoA:cholesterol acyltransferase inhibitor with improved aqueous solubility.](#)  
*4-Aryl-1,8-naphthyridin-2(1H)-on-3-yl urea derivatives with hydrophilic...*22nd March, 2006  
Research Division, Sumitomo Pharmaceuticals Co., Ltd 1-98, Kasugadenaka- Bioorg Med Chem Lett. 2006 Jan 1;16(1):44-8. Epub 2005 Oct 18. ([DOI Direct Link](#))
  - [Design, synthesis, and structure-activity relationships of 3,4-dihydropyridopyrimidin-2\(1H\)-one derivatives as a novel class of sodium/calcium exchanger inhibitor.](#)  
*Design, synthesis, and structure-activity relationships for...*4th February, 2006  
Research Division, Sumitomo Pharmaceuticals Co., Ltd., Osaka, Japan.- Chem Pharm Bull (Tokyo). 2005 Oct;53(10):1236-9.
  - [Reduction of myocardial infarct size by SM-197378, a novel Na<sup>+</sup>/H<sup>+</sup> exchange inhibitor, in rabbits.](#)  
*The effects of SM-197378,...*26th January, 2006  
Sumitomo Pharmaceuticals Co., Ltd., Research Division, Japan.- Eur J Pharmacol. 2005 Oct 3;521(1-3):115-23. Epub 2005 Sep 23. ([DOI Direct Link](#))
  - [\[Liposomal amphotericin B\]](#)  
*Liposomal amphotericin B (AmBisome) is a DDS (drug delivery system)...*21st January, 2006  
Sumitomo Pharmaceuticals Co., Ltd., Product Development Division, Tokyo,- Nippon Ishinkin Gakkai Zasshi. 2005;46(4):229-31.
  - [Discovery of hydroxamic acid analogs as dual inhibitors of phosphodiesterase-1 and -5.](#)  
*HTS and the following synthesis of a series of the compounds led us to the...*13th December, 2005  
Research Division, Sumitomo Pharmaceuticals Co., Ltd, 3-1-98 Kasugadenaka,- Bioorg Med Chem Lett. 2005 Sep 15;15(18):4085-90. ([DOI Direct Link](#))
  - [New 24-membered macrolides SPA-6952A and B produced by Streptomyces sp.](#)  
*Two new 24-membered macrolides, SPA-6952A and B, were isolated from the...*4th October, 2005  
Exploratory Research Group, Research Division, Sumitomo Pharmaceuticals- J Antibiot (Tokyo). 2005 Jun;58(6):409-11. ([DOI Direct Link](#))
  - [Antimycins A10 approximately A16, seven new antimycin antibiotics produced by Streptomyces spp. SPA-10191 and SPA-8893.](#)  
*Seven new antimycin antibiotics, named antimycins A10, A11, A12, A13, A14,...*30th September, 2005  
Exploratory Research Group, Research Division, Sumitomo Pharmaceuticals Co- J Antibiot (Tokyo). 2005 Jul;58(7):460-7. ([DOI Direct Link](#))
  - [\[In vitro combined effect of meropenem and various antimicrobial agents against beta-lactamase-nonproducing ampicillin-resistant Haemophilus influenzae and penicillin-resistant Streptococcus pneumoniae\]](#)  
*As a basic study of combination therapy for bacterial meningitis, in vitro...*20th August, 2005  
Discovery Research Laboratories II, Research Division, Sumitomo- Jpn J Antibiot. 2005 Apr;58(2):168-78.

**Press Releases on Sumitomo Pharmaceuticals Co Limited:**

<a href="#">Frost &amp; Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market</a>	26th November, 2009	Frost & Sullivan	<i>JOHANNESBURG, South Africa, Nov. 26 /PRNewswire/ -- The 2009 Frost &amp; Sullivan South Africa Company of the Year Award in the Generic Pharmaceutical Market is presented to Cipla Medpro South Africa</i>
<a href="#">"As an Industry, We've Been too Focused on Regulatory Approval," Says Solvay Pharmaceuticals Eric Rambeaux at the Pharma Marketing Summit.</a>	26th November, 2009		<i>LONDON, November 26 /PRNewswire/ -- Rambeaux joined a host of other industry leaders at eyeforpharma's 9th annual Pharma Marketing Summit 2009 conference in Berlin, where several key themes</i>
<a href="#">Onyx Pharmaceuticals Announces December 2009 Investor Events</a>	25th November, 2009	Onyx Pharmaceuticals, Inc.	<i>EMERYVILLE, Calif., Nov. 25 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the company will host two investor events in December: ASH Briefing December 7,</i>
<a href="#">dazzlesmile Sues Epic Advertising and Jesse Willms</a>	25th November, 2009	dazzlesmile, llc	<i>SALT LAKE CITY, Nov. 25 /PRNewswire/ -- dazzlesmile, llc www.dazzlesmile.com and Optimal Health Science, LLC www.optimalhealthscience.com have filed a 67-page federal lawsuit against Epic Advertising</i>
<a href="#">China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits</a>	25th November, 2009	China Sky One Medical, Inc.	<i>HARBIN, China, Nov. 25 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated</i>

## BioNews Results for Sumitomo Pharmaceuticals Co Limited



- [Global market for anti-depressants on a decline](#)  
*News-Medical.Net: Nov 20 2009 11:09AM Matching: sumitomo pharmaceuticals*
- [Research and Markets: Central Nervous System Therapeutics - A Comprehensive World Market Review of Geographic](#)  
*RBC Dain Rauscher: Nov 19 2009 4:52PM Matching: sumitomo pharmaceuticals*
- [Research and Markets: Central Nervous System Therapeutics - A Comprehensive World Market](#)

## [Review of Geographic](#)

*Business Wire via Yahoo!: Nov 19 2009 4:50PM Matching: sumitomo pharmaceuticals*

- [Research and Markets: Central Nervous System Therapeutics - A Comprehensive World Market Review of Geographic](#)

*Business Wire: Nov 19 2009 4:41PM Matching: sumitomo pharmaceuticals*

- [Research and Markets: Central Nervous System Therapeutics - A Comprehensive World Market Review of Geographic Coverage and Vertical Market Analysis](#)

*Business Wire UK: Nov 19 2009 4:35PM Matching: sumitomo pharmaceuticals*

- [Research and Markets: Central Nervous System Therapeutics - A Comprehensive World Market Review of Geographic Coverage and Vertical Market Analysis](#)

*Street Insider: Nov 19 2009 4:42PM Matching: sumitomo pharmaceuticals*

- [Japan Stock Market Ends In Negative Territory; Drug Makers Slip](#)

*Quote.com Singapore: Nov 12 2009 11:04AM Matching: sumitomo pharmaceuticals*

- [Dainippon Sumitomo Pharma Co., Ltd. and Sepracor Inc. Announce Completion of Subsequent Offering Period and Exercise of](#)

*NewsBlaze: Oct 20 2009 12:33PM Matching: sumitomo pharmaceuticals*

- [Dainippon Sumitomo Pharma Co., Ltd. and Sepracor Inc. Announce Successful Tender Offer and Commencement of Sub](#)

*NewsBlaze: Oct 14 2009 7:45AM Matching: sumitomo pharmaceuticals*

- [Dainippon Sumitomo Pharma to Acquire Sepracor for U.S. \\$23.00 Per Share in an All-Cash Tender Offer Valued at](#)

*Pharma Live: Sep 3 2009 12:44PM Matching: sumitomo pharmaceuticals*

## **Sumitomo Pharmaceuticals Co Limited Patents:**



- 4582845- [Pharmaceutical composition for injection](#)
- 5266596- [L- or DL-threo-3-\(3,4-dihydroxyphenyl\)serine for the treatment of urinary incontinence](#)
- 5310897- [Beta-lactams and their production](#)
- 5328903- [Composition for solid pharmaceutical preparations containing vitamin D3 derivative](#)
- 5424422- [Beta-lactams and their production](#)
- 5556860- [Quinazolinone derivatives possessing calcium uptake inhibiting activity](#)
- 5578722- [Process for preparing carbapenem compounds](#)
- 5607948- [Dipiperidine derivatives](#)
- 5639627- [Method for assaying specific antibody](#)
- 5236704- [Controlled release formulation](#)
- 5234691- [Sustained-release preparation of basic medical agent hydrochloride](#)
- 5227376- [.beta.-lactam compounds and their production](#)
- 4728729- [Cyanoimidazole nucleoside derivatives](#)
- 4933333- [.beta.-lactam compounds](#)
- 4943569- [B-lactam compounds](#)
- 4952566- [Stabilized anthracycline preparation containing L-cysteine](#)
- 5122604- [.beta.-lactam compounds](#)
- 5171219- [Pharmaceutical preparation administrator](#)
- 5216186- [Crystalline palladium tetrakis\(triphenylphosphine\) and a process for preparing the same](#)

- 5225422- [Pyridine compounds which are useful as leukotriene B4 antagonist](#)
- 5646154- [Pharmaceutical compositions for inhibiting the formation of tumor necrosis factor](#)
- 5656669- [Restorative neuropharmacological agent for motor and speech disturbance](#)
- 6391312- [Remedies for diabetes](#)
- 6399658- [Composition containing ascorbic acid](#)
- 6576656- [Oxindole derivative](#)
- 6673543- [Solid phase synthesis of LXR ligands](#)
- 6756358- [Therapeutic agent for cartilaginous diseases](#)
- 6759429- [Pyrrole derivatives](#)
- 6869609- [Method for treatment of renal failure and occlusive lesion of blood vessels by administration of hepatocyte growth factor](#)
- 6939887- [Benzimidazolidinone derivatives](#)
- 6303126- [Treatment of fibrosis by HGF](#)
- 6297019- [Recombinant polynucleotides encoding CYP7 promoter-binding factors](#)
- 6265396- [.beta.-lactam compounds and process for preparing the same](#)
- 5719152- [Tricyclic quinoxalinedione derivatives](#)
- 5840311- [Agent accelerating collagen decomposition](#)
- 5851547- [Controlled release drug formulation of open end cylindrical rod form](#)
- 5958697- [Isolated nucleic acids encoding CYP7 promoter-binding factors](#)
- 5977310- [Peg-modified HGF](#)
- 6027901- [CYP7 promoter-binding factors](#)
- 6194461- [Nitron derivatives](#)
- 6248772- [Indoloylguanidine derivatives](#)
- 7067528- [1, 2-dihydro-2-oxo-1, 8-naphthyridine derivative](#)

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

